Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6201312 | Ophthalmology | 2014 | 10 Pages |
Abstract
The systemic pharmacokinetics of ranibizumab were similar among patients with AMD, RVO, or DME. Disease-related differences and patient demographics, measured in this study, did not lead to variability in ocular elimination or in systemic exposure of ranibizumab after intravitreal administration. In all disease processes tested, ranibizumab exits the eye slowly and then is eliminated rapidly from the circulation, thus minimizing systemic exposure.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Yi PhD, Zhenling PhD, Nitin PhD, Peter PharmD, Jennifer PhD, Mauricio PhD, Lisa PharmD, Jason S. MD, PhD, Roman G. MD, Peter A. MD,